Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival - Scorecard - MDSpire
Advertisement
Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival
Clinical Scorecard: Impact of Noncompliance on Drug Survival in Moderate-to-Severe Psoriasis: A Retrospective Cohort Analysis of Immunobiological Treatments
At a Glance
Category
Detail
Condition
Moderate-to-Severe Psoriasis
Key Mechanisms
Distribution problems, poor adherence, and inadequate storage of immunobiological therapeutics.
Target Population
Adult patients with severe plaque psoriasis (PASI > 10, BSA > 10, or DLQI > 10).
Care Setting
Real-world registry for institutional follow-up.
Key Highlights
Adalimumab was the most frequently administered biologic.
Distribution problems were linked to increased treatment interruptions.
Lower drug survival rates reported in Brazil compared to international standards.
Study utilized a longitudinal registry for data collection.
Primary endpoint was drug survival duration from initiation to discontinuation.
Guideline-Based Recommendations
Diagnosis
Diagnosis of severe plaque psoriasis defined by PASI, BSA, or DLQI criteria.
Management
Initiation of immunobiological therapy based on severity and patient history.
Monitoring & Follow-up
Regular assessment of adherence, distribution issues, and storage conditions.
Risks
Increased risk of treatment interruption due to distribution problems and poor adherence.
Patient & Prescribing Data
Patients with moderate-to-severe psoriasis accessing treatment through public health or private insurance.
Access to biologics includes adalimumab as first-line and other agents as second-line options.
Clinical Best Practices
Ensure proper storage and adherence to prescribed biologic therapy.
Monitor for distribution issues to minimize treatment interruptions.
Utilize registry data for ongoing patient management and follow-up.
by Luciana A. Ribeiro, Patrícia S. Kurizky, Rodrigo R. de Sena, Samia Fares, Gabriel B. F. dos Santos, Letícia O. Galvão, Licia Maria H. da Mota, Ciro M. Gomes
Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.
